●Table 2B-3 and Appendix F: Removed MIC breakpoints which are no longer considered reliable for Burkholderia cepacia complex. Added instructions for handling B. cepacia complex should AST be requested. Developed ECVs for B. ...
The MIC breakpoints serve as a reference range to differentiate between susceptible, intermediate, and resistant isolates of Acinetobacter spp.to various antimicrobial agents. MIC折点作为参考范围,用于区分对各种抗微生物剂的不动杆菌属分离株的敏感、中间和耐药菌株。 For the testing of Acinetobacter spp.,...
[6] Huse HK, Miller SA, Chandrasekaran S, et al. Evaluation of oxacillin and cefoxitin disk diffusion and MIC breakpoints established by the Clinical and Laboratory Standards Institute for detection ofmecA-mediatedoxacillin resistance in ...
●Table 2B-3 and Appendix F: Removed MIC breakpoints which are no longer considered reliable for Burkholderia cepacia complex. Added instructions for handling B. cepacia complex should AST be requested. Developed ECVs for B. cepacia complex and added these to Appendix F. ●表2B-3和附件F:删除...
Where available, MICs were interpreted using CLSI 2010 MIC breakpoints (g/ml): ≤ 0.5 (S), 1 (I), ≥ 2 (R) for ETP and ≤1 (S), 2 (I), and ≥ 4 (R) for IPM/MEM/DOR. For evaluable ENT isolates we compared susceptibility results as reported by the facility to CLSI MIC ...
[6] Huse HK, Miller SA, Chandrasekaran S, et al. Evaluation of oxacillin and cefoxitin disk diffusion and MIC breakpoints established by the Clinical and Laboratory Standards Institute for detection ofmecA-mediatedoxacillin resistance in Staphylococcusschleiferi.J Clin Microbiol 2018; 56(2): e01653...
“Breakpoint”或称“cut-off” 抗菌药物对细菌MIC值的分布( S、I、R) 3种 “折点 ” 微生物(野生型折点 wild-type Breakpoint )在EUCAST中也称“Microbiological cut-off”, 临床治疗有效标准(折点) 与对引起感染病原体采用抗菌药物治疗成功/失败可能性相关的MIC 在EUCAST也称“epidemiologic cut-off ECOFF...
中文:酵母样真菌纸片扩散药敏试验的抑菌圈判断标准,相关的MIC折点解释标准和质量控制限制 英文:Zone Diameter Interpretive Standards, Corresponding Minimal Inhibitory Concentration (MIC) Interpretive Breakpoints, and Quality Control Limits for Antifungal Disk Diffusion Susceptibility Testing of Yeasts 内容与解释:略...
(FDA 13年2月1日批准),纸片扩散法 MIC法 如E-试验等,46,47,Additional CLSI Changes and Topics Under Evaluation,Continuing reevaluation of breakpoints Enterobacteriaceae cefepime Acinetobacter and other non Enterobacteriaceae carbapenems Fluoroquinolones and others Colistin / Polymyxin B Reexamine best met 17...
第32页/共48页头孢菌素治疗42例产ESBL的大肠和肺克临床及预后OutcomeMIC<=1ug/mlMIC2ug/mlMIC4ug/mlMIC8ug/ml成功13(81%)4(67%)3(27%)1(11%)失败3(19%)2(33%)8(73%)8(89%)第33页/共48页EUCAST同CLSI折点的差异第34页/共48页Notethus,wherethesenewbreakpointsareemployed,specificESBLtesting,...